ATLANTA--(BUSINESS WIRE)--MIV Therapeutics, Inc. (OTC/BB:MIVT) (Frankfurt:MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that its board of directors has unanimously approved a one-for-10 reverse stock split of the company’s approximately 116 million issued and outstanding common shares. The reverse split is part of a strategy to maximize shareholder value. As a result of the reverse split, a new trading symbol will be assigned.
